Tag archive for ‘Windtree Therapeutics’
Discovery Laboratories (DSCO): An Update and Buy Re-iteration
I have just published a new report on Discovery Laboratories; this emerging company has two products approved for U.S. marketing with Surfaxin and Afectair and controls worldwide rights to these products with the exception of Surfaxin in Spain and Portugal. It also has a highly promising pipeline. Surfaxin LS is a meaningful improvement over Surfaxin […]
Equity Offering Provides Discovery Laboratories Much Needed Financial Strength (DSCO, $2.81)
Report Summary With a number of cash infusions from a public offering, an ATM drawdown and warrant exercises, Discovery Laboratories (DSCO) has built a strong cash position. There remain a number of possible scenarios for how much more cash will come into the company depending on the exercise of the Green Shoe associated with the […]
Surfaxin Should Be Approved on its March 6th PDUFA Date (DSCO, $2.82)
Investment Thesis and Valuation The transformation of a biotechnology company from development stage to commercial can be the catalyst for a sustained increase in stock price. Discovery Laboratories (DSCO) received regulatory approval for its first product, Afectair, on February 2, 2012 and I believe that there is a strong possibility for approval of a second […]